Has Islam Abudayyeh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $153,528 in general payments to Islam Abudayyeh, MD across 264 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Islam Abudayyeh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Islam Abudayyeh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Islam Abudayyeh, MD

Interventional Cardiology · Redlands, CANPI 1356451785

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $133,656 of the $153,528 with a category attached, or 87.1%. 12 manufacturers reported payments, led by Edwards Lifesciences at 51.1% of the total. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$153,528in general payments, 2019–2025

Across 264 payments — averaging $581.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$79K
W. L. Gore & Associates, Inc.$68K
Medical Device Business Services, Inc.$3K
Medtronic$1K
Abbott$1K
Abiomed$635
plus $690 from 6 others

$46,415in research payments, 2019–2025

Across 17 payments — averaging $2730.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

W. L. Gore & Associates, Inc.$19K
Daiichi Sankyo Inc.$18K
Amgen$9K

What the payments were for

Consulting fees$133,65687%
Grants$1250%
Travel & lodging$12,4038%
Food & beverage$7,2045%
Education$1400%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	142	$78,518
W. L. Gore & Associates, Inc.	55	$67,899
Medical Device Business Services, Inc.	1	$3,000
Medtronic(2 entities)	16	$1,476
Abbott	24	$1,309
Abiomed	17	$635
Boston Scientific	2	$300
Biotronik Inc.	3	$186
Biosense Webster, Inc.	1	$150
Philips North America LLC	1	$24
Teleflex LLC	1	$16
Cordis US CORP.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Edwards SAPIEN 3 Transcatheter Heart Valve$73,549
GORE CARDIOFORM Septal Occluder$60,259
GORE CARDIOFORM ASD Occluder$36,430
Carto 3$3,000
CARDIOFORM Septal Occluder$2,680
COREVALVE EVOLUT R$824
Product in Development$670
TRICLIP$646
Edwards SAPIEN XT Transcatheter Heart Valve$370
Avalus$188
GENERAL - THERAPIES$175
Impella$173
NUVISION ICE CATHETER$150
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$141
Resolute$140
Mitra Clip system$138
NAVITOR$128
SAPIEN 3 Ultra RESILIA$115

How this compares

$153,528 in reported general payments places this provider in the 90th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California →

Medicare billing

Part B allowed, 2024

$7,941

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Memantine Hcl	18	$399
Donepezil Hcl	16	$270

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Redlands

Matthew Pricela Jolla$2.3M
Frederick St GoarMountain View$2.2M
Saibal KarThousand Oaks$1.1M
Rahul SharmaStanford$1M
Puneet KhannaRancho Mirage$1M
Dennis SheehanRedwood City$900K
Suhail DohadBeverly Hills$802K
Curtiss Stinisla Jolla$759K
Christian SpiesBurlingame$719K
Evan ZahnLos Angeles$632K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →